Cases

  • Hanmi/Beijing Hanmi, Innovent agree to co-
    develop bispecific anticancer antibody

    Hanmi Pharmaceuticals and Innovent Biologics signed
    a global partnership to develop a immuno-oncology bispecific antibody

  • License agreement with Genentech for a novel
    oral RAF inhibitor

    Hanmi enters into an exclusive development with Genentech for the development and commercialization
    of Hanmi’s pan-RAF inhibitor, HM95573, which is currently in Phase I clinical development

  • Hanmi-MSD sign contract to export
    ROSUZET to 23 countries

    Hanmi Pharm responsible for R&D and manufacturing of ROSUZET; MSD responsible for marketing and sales in importing countries

  • Research collaboration for new anti-cancer drug with Ajou Univ.

    Research collaboration to develop novel anti-cancer drug using stem cells covering glioblastoma and various cancer

  • Licensing agreement for new lung cancer drug with ZAI Lab

    Licensing agreement to grant exclusive rights in China (including Hong Kong and Macao) for new lung cancer drug targeting resistance, HM61713, with ZAI Lab, a biotechnology company based in Shanghai, China

  • Technology transfer of new biologics to Janssen

    Licensing agreement for development and commercialization of long-acting GLP-1/Glucagon receptor dual agonist ‘HM12525A’ for the treatment of diabetes and obesity with Janssen, a pharmaceutical company based in New Jersey, USA

  • Technology transfer of new diabetes program to Sanofi

    Licensing agreement for Quantum Project, a long-acting diabetes program, with Sanofi, a pharmaceutical company based in Paris, France

  • Licensing agreement for immunological therapy with Eli Lilly

    Exclusive licensing and collaboration agreement for BTK inhibitor, HM71224, with Eli Lilly, a pharmaceutical company based in Indiana, USA

  • License out Poziotinib to Spectrum (US)

    Worldwide licensing agreement excluding Korea and China, for clinical development, manufacturing, marketing approval and commercialization of Poziotinib with Spectrum baseed in Nevada State, USA

  • Strategic investment in US R&D venture specialized in ophthalmology

    License and co-development rights of Luminate® , novel drug for a retina-related disease, through strategic investment in Allegro Ophthalmics based in California, USA

  • License out Poziotinib to Luye Pharma (China)

    Exclusive licensing agreement for clinical development, manufacturing and approval and sales and marketing after commercialization of Poziotinib in China with Luye Pharma, based in Yantai, China

  • Co-promotion for diabetes medicines with multinational pharmaceutical company

    Co-promotion of anti-diabetic treatment Galvus ® and Galvus MET®, DPP-IV inhibitors, with Novartis, a Swiss multinational pharmaceutical company

  • Licensing agreement for new drug for neutropenia

    Licensing agreement for worldwide license, excluding Korea, China and Japan, for a new medicine for neutropenia with Spectrum based in California, USA

  • Export of ORASCOVERY technology to Athenex (US)

    Licensing agreement with Anthenex, headquatered in NY, for development and commercialization in the US, Europe, etc. of ORASCOVERY technology and a new oral anticancer drug developed using this technology.